Women First HealthCare acquires Vaniqa, plans relaunch

Article

San Diego - With its acquisition from Bristol-Myers Squibb of worldwide rights and title to Vaniqa (eflornithine hydrochloride) Cream, Women First HealthCare plans to take another pass at providing women with hirsutism a pharmaceutical alternative.

Related Videos
Related Content

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023
© 2023 MJH Life Sciences

All rights reserved.